Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.88 Average Target Price from Analysts
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...
Zacks.com on MSN1d
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TD Cowen Reaffirms Their Buy Rating on Amicus (FOLD)
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00.
Hosted on MSN1d
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Travere Therapeutics (TVTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
New Jersey Business21h
BioNJ Elects Board Officers and Trustees
Life sciences trade association BioNJ has announced the election of its 2025 Officers and Board Members in concert with BioNJ ...
Yahoo Finance5d
Amicus Therapeutics, Inc. (FOLD)
Pre-Market: 8:58:38 a.m. EST ...